Loading Events

Sermonix Pharmaceuticals KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape

Banners (55)
DATE: April 22, 2024
TIME: 12:00 PM EDT

About The Event

Join Sermonix Pharmaceuticals for a virtual KOL fireside chat, featuring Senthil Damodaran MD, PhD (MD Anderson Cancer Center) and Seth Wander, MD, PhD (Harvard Medical School, Massachusetts General Hospital) to discuss the unmet need and current treatment landscape for metastatic breast cancer.

The event will focus on the Company’s ELAINE (Evaluating Lasofoxifene in ESR1 Mutations) studies investigating lasofoxifene in patients with locally advanced or metastatic estrogen receptor-positive/human epidermal growth factor 2-negative (ER+/HER2-) breast cancer expressing an estrogen receptor 1 (ESR1) mutation.

With Phase 2 ELAINE-1 and ELAINE-2 studies both completed and having demonstrated compelling anti-tumor activity against tumors with increasingly prevalent ESR1 mutations, enrollment is currently open for ELAINE-3, a large, randomized, Phase 3 study with clinical trial sites across the United States, Europe, Asia-Pacific, Israel, and Canada.

A live question and answer session will follow the formal presentations.